SCM
TVRD

Sterling Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Sterling Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$515 Sell
162
-130
-45% -$509 ﹤0.01% 3153
2025
Q4 		$1.26K Buy
292
+3
+1% +$27 ﹤0.01% 3123
2025
Q3 		$11.3K Buy
289
+207
+252% +$5.89K ﹤0.01% 2425
2025
Q2 		$1.91K Buy
+82
New +$1.94K ﹤0.01% 2927

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $361M AUM 18% 1-Year Est. Return

Sterling Capital Management's TVRD Position: Q1 2026 in Review

Sterling Capital Management reduced its Tvardi Therapeutics (TVRD) stake by 45% in Q1 2026, selling an estimated $509 and leaving 162 shares worth $515. The position accounts for ﹤0.01% of the portfolio, ranked #3153.

Sterling Capital Management first reported a position in TVRD in Q2 2025 and has held it in 4 quarters since. The position peaked at $11.3K in Q3 2025. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • Sterling Capital Management held 162 shares of Tvardi Therapeutics worth $515 as of Q1 2026.
  • Sterling Capital Management sold 130 Tvardi Therapeutics shares in Q1 2026, an estimated $509.
  • Tvardi Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #3153 holding.
  • Sterling Capital Management first reported a position in Tvardi Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Sterling Capital Management's Tvardi Therapeutics position peaked at $11.3K in Q3 2025.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.